Vie Ventures

Vie Ventures bridges venture capital with disease philanthropy to develop breakthrough therapies, primarily for autoimmune diseases. The firm leverages deep experience in life sciences investing and a network of strategic collaborators. This model accelerates scientific discoveries into effective clinical solutions.

Co-founded by Steven St. Peter, M.D., and Luke Evnin, M.D., both seasoned biotech investors, Vie Ventures emerged from a recognition that combining traditional venture capital with disease-focused philanthropy could create a more efficient funding pathway. This approach utilizes philanthropic capital and patient expertise to address unmet medical needs.

The firm targets patients requiring novel treatments for autoimmune diseases. Vie Ventures' long-term vision is to transform therapeutic development by fostering an ecosystem where scientific advancement, financial returns, and philanthropic objectives converge. It strives to accelerate the availability of life-changing therapies, creating substantial impact for affected individuals.

High-Level Overview

Vie Ventures is a life sciences venture capital firm launched in July 2025, uniquely positioned at the intersection of traditional VC and disease-focused philanthropy to accelerate breakthrough therapies for autoimmune diseases and immune system disorders.[1][2][3] Its mission is to generate attractive financial returns while delivering mission-driven impact by investing in Series B and C-stage private biotech companies developing next-generation therapeutics in areas of significant unmet need, such as autoimmune conditions experiencing rapid biotech innovation.[1][3] The firm participates in equity syndicates alongside leading VCs and strategic partners, leveraging a network from biotech and philanthropy ecosystems to provide value-added support, including patient perspectives and research expertise.[1][4][5] This approach bridges for-profit investing with philanthropic goals, catalyzing life-changing cures and influencing the startup ecosystem by de-risking development through cross-sector collaboration.[2][5]

Origin Story

Vie Ventures was officially launched on July 9, 2025, co-founded by Steven St. Peter, M.D., and Luke Evnin, Ph.D., both veteran life sciences investors with deep operational leadership experience.[3][4] St. Peter previously led the T1D Fund, growing it into one of the world's largest disease-focused venture philanthropy funds with over $200 million in assets, while Evnin co-founded MPM Capital and chairs the Scleroderma Research Foundation (SRF), where he has driven innovative research models like the CONQUEST clinical trial platform.[3] The idea emerged from their recognition of untapped synergies between VC capital and philanthropy in immunology, particularly amid surging innovation in autoimmune therapies; the firm quickly formed inaugural partnerships with organizations like the Lupus Research Alliance, Scleroderma Research Foundation, Crohn’s and Colitis Foundation, National Multiple Sclerosis Society, and Sjögren’s Foundation.[4][6] Early milestones include convening the first Therapeutics Advisory Council (TAC) on September 9, 2025, in New York City, uniting philanthropies, scientists, and investors to align on common biology and de-risk therapeutic pipelines.[5]

Core Differentiators

• Unique Investment Model: Invests alongside top VCs in late-stage (Series B/C) biotechs while integrating disease philanthropy for patient insights, research infrastructure, and de-risking, creating a hybrid approach that aligns financial returns with therapeutic impact.[1][3][4]
• Network Strength: Strategic collaborators from major patient organizations (e.g., Lupus Research Alliance, Scleroderma Research Foundation) provide unmatched expertise, patient networks, and cross-disease coalitions like the TAC to inform investments and accelerate innovation.[5][6]
• Track Record of Founders: Decades of proven VC success—St. Peter in venture philanthropy scaling, Evnin in biotech firm-building—combined with a returns-oriented strategy focused on high-unmet-need immunology.[2][3]
• Operating Support: Acts as a value-added partner via the TAC, fostering collaboration among foundations, industry, and investors to identify shared biology, advance clinical trials, and integrate patient perspectives into development.[1][5]

Role in the Broader Tech Landscape

Vie Ventures rides the wave of explosive innovation in autoimmune and immune-mediated diseases, where rapid biotech advances address massive unmet needs amid a surge in novel therapeutics.[1][3] Its timing is ideal, launching during a period of heightened VC interest in immunology post-2025, when cross-sector models are gaining traction to overcome high failure rates in drug development.[2][5] Market forces like aging populations, rising autoimmune prevalence, and philanthropy's push for bold research (e.g., shared trial platforms) favor its model, enabling faster derisking and broader ecosystem influence.[3][6] By uniting fragmented disease foundations with VC syndicates, it shapes the biotech landscape, promoting collaborative platforms like the TAC that could standardize innovation across conditions, ultimately pressuring traditional funds to adopt hybrid philanthropy-VC strategies.[4][5]

Quick Take & Future Outlook

Vie Ventures is poised to scale its TAC model, potentially expanding investments into adjacent immune disorders and convening more cross-disease coalitions to capture immunology's next innovation wave.[5] Trends like AI-driven drug discovery, personalized immune therapies, and increased philanthropic capital will amplify its hybrid approach, enhancing deal flow and impact.[2] Its influence may evolve from niche bridge-builder to ecosystem leader, drawing more patient orgs and VCs into aligned syndicates—ultimately proving that blending returns with philanthropy can redefine life sciences investing, much like its launch bridged untapped worlds to catalyze autoimmune breakthroughs.[1][3]